GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (FRA:SVQ) » Definitions » Capex-to-Operating-Income

Sinovac Biotech (FRA:SVQ) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sinovac Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sinovac Biotech's Capital Expenditure for the six months ended in Dec. 2023 was €-48.37 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-86.04 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Sinovac Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Sinovac Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Capex-to-Operating-Income Chart

Sinovac Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.59 0.04 - -

Sinovac Biotech Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.45 - - -

Competitive Comparison of Sinovac Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, Sinovac Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Capex-to-Operating-Income falls into.



Sinovac Biotech Capex-to-Operating-Income Calculation

Sinovac Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-133.596) / -480.784
=N/A

Sinovac Biotech's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-48.368) / -86.035
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (FRA:SVQ) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Sinovac Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (FRA:SVQ) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Sinovac Biotech (FRA:SVQ) Headlines

No Headlines